Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer

Biomaterials

Volumn 33, Issue 7, 2012, Pages 2272-2281

  Guo, Ding Ding ^a,c   Hong, Seong Ho ^a,c   Jiang, Hu Lin ^a   Kim, Ji Hye ^a,b   Minai Tehrani, Arash ^a   Kim, Ji Eun ^a,b   Shin, Ji Young ^a   Jiang, Tao ^a   Kim, You Kyoung ^a   Choi, Yun Jaie ^a   Cho, Chong Su ^a   Cho, Myung Haing ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c LANZHOU UNIVERSITY   (China)

Author keywords

Akt1; Breast cancer; Combination therapy; Conjugated linoleic acid; Paclitaxel; Poloxamer hydrogel

Indexed keywords

AKT1; BREAST CANCER; COMBINATION THERAPY; CONJUGATED LINOLEIC ACID; PACLITAXEL; POLOXAMER;

CELL DEATH; CHEMOTHERAPY; DISEASES; LINOLEIC ACID; ONCOLOGY; UNSATURATED FATTY ACIDS;

HYDROGELS;

ANTINEOPLASTIC AGENT; CASPASE 3; CONJUGATED LINOLEIC ACID; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE SHORT HAIRPIN RNA; POLOXAMER; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HEAT SENSITIVITY; HYDROGEL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROGEL; LINOLEIC ACIDS, CONJUGATED; MATERIALS TESTING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; POLOXAMER; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

MUS;

EID: 84855748506     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.12.011     Document Type: Article

References (53)

1. Soran A., Wu W.C., Dirican A., Johnson R., Andacoglu O., Wilson J. Estimating the probability of lymphedema after breast cancer surgery. Am J Clin Oncol 2011, 34:506-510.
2. Schmuth M., Wimmer M.A., Hofer S., Sztankay A., Weinlich G., Linder D.M., et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol 2002, 146:983-991.
3. Dorr W., Bertmann S., Herrmann T. Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects. Strahlenther Onkol 2005, 181:567-573.
4. Kizek R., Adam V., Hrabeta J., Eckschlager T., Smutny S., Burda J.V., et al. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. Pharmacol Ther 2011.
5. Bandyopadhyay A., Wang L., Agyin J., Tang Y., Lin S., Yeh I.T., et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5:e10365.
6. Kolosov A., Goodchild C.S., Cooke I. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med 2010, 11:262-273.
7. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006, 2:711-719.
8. Fire A.Z. Gene silencing by double-stranded RNA (Nobel Lecture). Angew Chem Int Ed Engl 2007, 46:6966-6984.
9. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
10. Banni S., Angioni E., Murru E., Carta G., Melis M.P., Bauman D., et al. Vaccenic acid feeding increases tissue levels of conjugated linoleic acid and suppresses development of premalignant lesions in rat mammary gland. Nutr Cancer 2001, 41:91-97.
11. Belury M.A. Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. JNutr 2002, 132:2995-2998.
12. Thompson H., Zhu Z., Banni S., Darcy K., Loftus T., Ip C. Morphological and biochemical status of the mammary gland as influenced by conjugated linoleic acid: implication for a reduction in mammary cancer risk. Cancer Res 1997, 57:5067-5072.
13. Ip C., Chin S.F., Scimeca J.A., Pariza M.W. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res 1991, 51:6118-6124.
14. Ip C., Dong Y., Ip M.M., Banni S., Carta G., Angioni E., et al. Conjugated linoleic acid isomers and mammary cancer prevention. Nutr Cancer 2002, 43:52-58.
15. Liew C., Schut H.A., Chin S.F., Pariza M.W., Dashwood R.H. Protection of conjugated linoleic acids against 2-amino-3- methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. Carcinogenesis 1995, 16:3037-3043.
16. Belury M.A., Nickel K.P., Bird C.E., Wu Y. Dietary conjugated linoleic acid modulation of phorbol ester skin tumor promotion. Nutr Cancer 1996, 26:149-157.
17. Kavanaugh C.J., Liu K.L., Belury M.A. Effect of dietary conjugated linoleic acid on phorbol ester-induced PGE2 production and hyperplasia in mouse epidermis. Nutr Cancer 1999, 33:132-138.
18. Masso-Welch P.A., Zangani D., Ip C., Vaughan M.M., Shoemaker S., Ramirez R.A., et al. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res 2002, 62:4383-4389.
19. Ma D.W., Field C.J., Clandinin M.T. An enriched mixture of trans-10, cis-12-CLA inhibits linoleic acid metabolism and PGE2 synthesis in MDA-MB-231 cells. Nutr Cancer 2002, 44:203-212.
20. Kemp M.Q., Jeffy B.D., Romagnolo D.F. Conjugated linoleic acid inhibits cell proliferation through a p53-dependent mechanism: effects on the expression of G1-restriction points in breast and colon cancer cells. JNutr 2003, 133:3670-3677.
21. Chujo H., Yamasaki M., Nou S., Koyanagi N., Tachibana H., Yamada K. Effect of conjugated linoleic acid isomers on growth factor-induced proliferation of human breast cancer cells. Cancer Lett 2003, 202:81-87.
22. Miglietta A., Bozzo F., Bocca C., Gabriel L., Trombetta A., Belotti S., et al. Conjugated linoleic acid induces apoptosis in MDA-MB-231 breast cancer cells through ERK/MAPK signalling and mitochondrial pathway. Cancer Lett 2006, 234:149-157.
23. Lim D.Y., Tyner A.L., Park J.B., Lee J.Y., Choi Y.H., Park J.H. Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1. JCell Physiol 2005, 205:107-113.
24. Yurawecz M.P., Hood J.K., Mossoba M.M., Roach J.A., Ku Y. Furan fatty acids determined as oxidation products of conjugated octadecadienoic acid. Lipids 1995, 30:595-598.
25. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006, 45:1198-1215.
26. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., et al. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. JControl Release 2001, 74:135-146.
27. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999, 5:83-94.
28. Caiolfa V.R., Zamai M., Fiorino A., Frigerio E., Pellizzoni C., d'Argy R., et al. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. JControl Release 2000, 65:105-119.
29. Hanada M., Feng J., Hemmings B.A. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 2004, 1697:3-16.
30. Brader S., Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004, 90:2-8.
31. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 16(Suppl. 1):12-19.
32. Dillon R.L., Muller W.J. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 2010, 70:4260-4264.
33. Sanchez-Munoz A., Perez-Ruiz E., Jimenez B., Ribelles N., Marquez A., Garcia-Rios I., et al. Targeted therapy of metastatic breast cancer. Clin Transl Oncol 2009, 11:643-650.
34. Dillon R.L., White D.E., Muller W.J. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26:1338-1345.
35. Guo D.D., Xu C.X., Quan J.S., Song C.K., Jin H., Kim D.D., et al. Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel invitro and invivo. Biomaterials 2009, 30:4777-4785.
36. Xu C.X., Jere D., Jin H., Chang S.H., Chung Y.S., Shin J.Y., et al. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med 2008, 178:60-73.
37. Guo D.D., Moon H.S., Arote R., Seo J.H., Quan J.S., Choi Y.J., et al. Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells. Cancer Lett 2007, 254:244-254.
38. Park M.R., Han K.O., Han I.K., Cho M.H., Nah J.W., Choi Y.J., et al. Degradable polyethylenimine-alt-poly(ethylene glycol) copolymers as novel gene carriers. JControl Release 2005, 105:367-380.
39. Matthew J.E., Nazario Y.L., Roberts S.C., Bhatia S.R. Effect of mammalian cell culture medium on the gelation properties of Pluronic F127. Biomaterials 2002, 23:4615-4619.
40. West K.A., Brognard J., Clark A.S., Linnoila I.R., Yang X., Swain S.M., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. JClin Invest 2003, 111:81-90.
41. Leonardi E., Girlando S., Serio G., Mauri F.A., Perrone G., Scampini S., et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. JClin Pathol 1992, 45:416-419.
42. Bergsland E.K. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm 2004, 61:S4-11.
43. Chen J., Zeng J., Xin M., Huang W., Chen X. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways invitro and invivo. Horm Metab Res 2011, 43:681-686.
44. Ruggero D., Sonenberg N. The Akt of translational control. Oncogene 2005, 24:7426-7434.
45. Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. JCell Sci 2001, 114:2903-2910.
46. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
47. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
48. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511.
49. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002, 8:1136-1144.
50. Grana X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995, 11:211-219.
51. Schiff P.B., Horwitz S.B. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry 1981, 20:3247-3252.
52. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Huang M., et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000, 20:407-416.
53. Niklinska W., Burzykowski T., Chyczewski L., Niklinski J. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer 2001, 34(Suppl. 2):S59-S64.